Frequently Asked Questions

Study Specific Questions

To participate in this study, you or a loved one must:

  • Be age 30 and older
  • Have a clinical diagnosis of Parkinson’s Disease
  • Not currently be receiving any medication for Parkinson’s Disease
  • Have not previously received any medication for Parkinson’s Disease for more than 28 total days at a time
  • Be freely ambulatory (with or without assistive device)

There are additional criteria that are reviewed by the study team during your first appointment.

You will meet with a study coordinator at a study site location closest to you. You will learn more about the research study and the benefits and risks of participation.

The study coordinator or study doctor will review the Informed Consent Form with you. You will have the chance to ask any questions about this form, and sign once comfortable and willing to participate in the study. Different procedures will be performed to see if you qualify for the clinical study.

CVN424 is a new molecule that blocks GPR6, a receptor mostly found in the so-called “indirect pathway” of the brain, which works as a brake on several brain functions. The indirect pathway becomes overactive in Parkinson’s disease, causing slowness of movements, difficulty thinking and problems with motivation and mood. Blocking GPR6, CVN424 can decrease the activity of the indirect pathway (“the brake”) and can improve motor as well as some non-motor manifestations of Parkinson’s disease.

This study will include screening, treatment, and follow-up periods. Screening for the study can take up to 4 weeks. During this time, study doctors will ask you medical questions and conduct health tests to determine if you qualify for this study. The screening period occurs before you get assigned to your treatment group.

If you are eligible to participate, you will return to the study site for up to 7 visits with 2 telephone visits over the course of 14 weeks (12-week treatment period + 2-week follow up period) to monitor your progress as well as your overall health. CVN424 is taken orally (by mouth) once daily, specifically with the largest meal of the day. It is ideal to take this at the same time every day.

The 25 study centers are located throughout the United States. Please see study location section for details.

You do not have to stop taking your medication unless you are advised to do so by the study center staff or your primary care physician.

No, there will be no cost to you for the study therapy or study procedures.

No, health insurance is not a requirement to participate in either study.

Questions About Clinical Research Studies

Clinical trials, also known as clinical studies or research studies are conducted by doctors and researchers to see if new medications or treatments are safe and effective before being approved for use by the general public. Participation in a clinical trial is completely confidential and will be protected just like any other medical information.

Research studies are used to test new medications for safety, tolerability, and effectiveness before they are approved for use by the public.

You can find out more information about clinical trials by browsing through www.clinicaltrials.gov. This is an online, government database that is managed by the National Library of Medicine. It provides information about both federally and privately supported clinical research studies.

All research studies require that doctors and/or researchers give interested participants complete and accurate information about the risks, benefits and activities of a research study. Interested participants will sign an Informed Consent Form prior to enrolling in the study. This form shows that a participant understands what will happen during the study and that they can leave the study at any time.

Scroll to Top

Refer A Friend

Do you know someone age 30 or older who has Parkinson’s Disease? They may be eligible to participate in the ASCENDsstudy. Consider sharing information with them about how they can learn more.